Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Algernon, Biontech, Clarity, Janssen, Mallinckrodt, Novartis, Pfizer, Vitro.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ablexis, Alkermes, Alpha Cognition, Anticancer, Applied Biomath, Asklepios, Avacta, Bayer Bonus Biogroup, Brainvectis, Caladrius, Cellphire, Cocrystal Pharma, Cormedix, Cyclica, Emergex Vaccines, Envisagenics, Etherna, Evotec, Frame, Gilead, Hoth, Immunic, Johnson & Johnson, Kalos, Kite, Linical, Northern Biologics, Nuritas, Oncology Venture, Onko-innate, Pharnext, Q Biomed, Sanofi, Som, Targovax, Valo, Wize, Wuxi, Zylö Therapeutics.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actelion, Astrazeneca, Bluebird, Boehringer, Exelixis, GSK, Harbour, Imbrium, Immutep, Incyte, Intra-Cellular, Kiniksa, Levo, Lilly, Prothena, Neoimmunetech, Regeneron, Regenxbio, Roche, Saniona, Sojournix, Tersera, UCB, United Therapeutics.

Biopharmas raising money in public or private financings, including: Actinium, Arcturus, Calithera, Cyclacel, Forx, Myosana, Migvax, Realta Life Sciences, VBI.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied Therapeutics, Arcutis, Atyr, Cara, Catalyst, CSL Behring, Erytech, Hookipa, Idera, Novartis, Oncoimmune, Synexis.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainlab, Inspire Medical Systems, Labcorp, Roche.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advarra, Amc Health, Archerdx, Centogene, Cerus, Curetis, Evicore Healthcare, Karolinska Institutet, Kurin, Opgen, Oxford Immunotec, Premier, Science 37, Simplify Medical, Vizient.

LONDON – The search for modulators of the immune cascade that is the cause of the most severe respiratory symptoms of COVID-19 is intensifying, with Cyclacel Pharmaceuticals Inc. and Pharming Group NV adding their drugs to the list of repurposing projects.

Privately held Memgen LLC and the H. Lee Moffitt Cancer Center agreed to technology licensing agreements covering intellectual property the two jointly developed. The deal includes MEM-288, Memgen’s lead candidate, which the company said exhibits significantly enhanced selectivity and activity against a range of tumor types.